Nestlé is reformulating some of its products to account for the dulled taste perception that can accompany GLP-1 weight loss drugs, according to The Wall Street Journal.
Marketing chief David Rennie said that shifting eating habits prompted the company to run packaged food trials with consumers to map out how GLP-1 use affects the way people experience flavor. "People don't want to eat as much on GLP-1s, and also your taste profile changes," Rennie said. "GLP-1s sort of dulls your taste profile." A study published in a 2025 volume of the Physiology & Behavior journal found that perception of the five basic taste qualities was depressed by GLP-1 drugs.
Rennie said GLP-1 users will be brought in as collaborators during recipe development, with potential adjustments ranging from heavier use of pepper to broader spice additions. Packaging, however, will not necessarily reflect the reformulations, Rennie noted. For users who prefer not to have their medication use foregrounded in their grocery choices, Rennie said Nestlé has opted for subtler interventions — overhauling nutrition label clarity and rethinking portion sizing rather than explicit GLP-1 branding.
Beyond its existing Vital Pursuit frozen meal line, which is designed for people on weight loss drugs, Rennie said Nestlé has been rolling out protein- and fiber-forward versions of mainstream products — citing a high-protein Milo chocolate malt drink as one example.
The snacking category is a particular focus. Within snacking specifically, Rennie said GLP-1 users tend to gravitate toward premium, reduced-size treats over conventional portion formats.
The moves come as food companies face pressure from the growing adoption of GLP-1 medications, which reduce appetite and lead users to eat smaller portions and fewer snacks. A growing number of large U.S. employers are pulling back on GLP-1 coverage heading into 2027 due to rising health care costs, even as per-unit drug prices have declined. The patient population continues to expand, including through new pill-form versions of the medications that have drawn in users who previously avoided injectable treatments — a dynamic that has kept overall costs elevated for employers despite lower unit prices.